Conditions: Recurrent Multiple Myeloma; Refractory Multiple Myeloma
Interventions: Biological: Allogeneic Defined Hematopoietic Stem Cells/Immune Cells; Biological: Allogeneic Defined Hematopoietic Stem Cells/Immune Cells; Drug: Busulfan; Biological: Filgrastim; Drug: Fludarabine; Drug: Granulocyte Colony-Stimulating Factor; Drug: Thiotepa
Sponsors: University of California, Davis; National Cancer Institute (NCI); Orca Biosystems, Inc.
Not yet **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
